Advertisement

CardioVascular and Interventional Radiology

, Volume 41, Issue 11, pp 1699–1707 | Cite as

Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate Lobe

  • Bo-Ching Lee
  • Kao-Lang Liu
  • Chih-Horng Wu
  • Kai-Wen Huang
  • Cheng-Maw Ho
  • Rey-Heng Hu
  • Ming-Chih Ho
  • Yao-Ming Wu
  • Po-Huang Lee
  • Po-Chin Liang
Clinical Investigation
  • 113 Downloads
Part of the following topical collections:
  1. Interventional Oncology

Abstract

Background and Aims

Hepatocellular carcinoma (HCC) in the caudate lobe is technically challenging for both radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). However, each of these modalities has its strengths. This retrospective study compares the effectiveness of RFA and TACE in patients with caudate HCC within the Milan criteria.

Methods

This study was approved by institutional review board. Between November 2005 and August 2016, we retrospectively reviewed 74 patients with a single HCC ≤ 5 cm or up to three HCCs ≤ 3 cm without vascular invasion or extrahepatic metastasis who were treated with RFA (n = 43) or TACE (n = 31). The overall survival (OS) and local progression rates were compared after propensity score analysis.

Results

The mean follow-up period was 2.8 ± 1.9 years. The 1-, 2-, and 3-year survival rates were 97.1, 94.0, and 80.7% for the RFA group and 89.0, 80.8, and 62.0% for the TACE group, respectively. The clinical variables of the RFA and the TACE groups were well balanced by propensity score adjustment, and the RFA group showed better OS (P = .039) and local progression rates (P = .004) than the TACE group.

Conclusions

RFA appears to outperform TACE for patients with caudate HCC within the Milan criteria and should be the favored treatment option when surgical resection is not feasible.

Keywords

Chemoembolization Humans Liver neoplasms/mortality Radiofrequency ablation Survival analysis Treatment outcome 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

This retrospective study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of our institution.

References

  1. 1.
    Tanaka S, Shimada M, Shirabe K, et al. Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg. 2005;190(3):451–5.CrossRefGoogle Scholar
  2. 2.
    Yamamoto T, Kubo S, Shuto T, et al. Surgical strategy for hepatocellular carcinoma originating in the caudate lobe. Surgery. 2004;135(6):595–603.CrossRefGoogle Scholar
  3. 3.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med. 1996;334(11):693–9.CrossRefGoogle Scholar
  4. 4.
    Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238(3):315–23.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Yang MC, Lee PO, Sheu JC, Lai MY, Hu RH, Wei CK. Surgical treatment of hepatocellular carcinoma originating from the caudate lobe. World J Surg. 1996;20(5):562–6.CrossRefGoogle Scholar
  6. 6.
    Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M. Limited hepatic resection for hepatocellular carcinoma in the caudate lobe. World J Surg. 2004;28(7):697–701.CrossRefGoogle Scholar
  7. 7.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.CrossRefGoogle Scholar
  8. 8.
    Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47(1):82–9.CrossRefGoogle Scholar
  9. 9.
    Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78(Suppl 1):113–24.CrossRefGoogle Scholar
  10. 10.
    Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115–22.CrossRefGoogle Scholar
  11. 11.
    Kariyama K, Nouso K, Wakuta A, et al. Percutaneous radiofrequency ablation for treatment of hepatocellular carcinoma in the caudate lobe. AJR Am J Roentgenol. 2011;197(4):W571–5.CrossRefGoogle Scholar
  12. 12.
    Takayasu K, Muramatsu Y, Shima Y, et al. Clinical and radiologic features of hepatocellular carcinoma originating in the caudate lobe. Cancer. 1986;58(7):1557–62.CrossRefGoogle Scholar
  13. 13.
    Lu CL, Wu JC, Chiang JH, Lui WY, Chau GY, Lee SD. Hepatocellular carcinoma in the caudate lobe: early diagnosis and active treatment may result in long-term survival. J Gastroenterol Hepatol. 1997;12(2):144–8.CrossRefGoogle Scholar
  14. 14.
    Terayama N, Miyayama S, Tatsu H, et al. Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol JVIR. 1998;9(3):501–8.CrossRefGoogle Scholar
  15. 15.
    Kim HC, Chung JW, Jae HJ, et al. Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology. 2010;257(1):278–87.CrossRefGoogle Scholar
  16. 16.
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.CrossRefGoogle Scholar
  17. 17.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.CrossRefGoogle Scholar
  18. 18.
    Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefGoogle Scholar
  19. 19.
    Nishigaki Y, Tomita E, Hayashi H, et al. Efficacy and safety of radiofrequency ablation for hepatocellular carcinoma in the caudate lobe of the liver. Hepatol Res. 2013;43(5):467–74.CrossRefGoogle Scholar
  20. 20.
    Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics: a review publication of the Radiological Society of North America, Inc, 2013; 33(5):1323–1341.CrossRefGoogle Scholar
  21. 21.
    Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–6.CrossRefGoogle Scholar
  22. 22.
    McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology. 2013;267(1):106–18.CrossRefGoogle Scholar
  23. 23.
    Ota K, Teraoka S, Kawai T. Donor difficulties in Japan and Asian countries. Transplant Proc. 1995;27(1):83–6.PubMedGoogle Scholar
  24. 24.
    Seror O, Haddar D, N’Kontchou G, et al. Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. J Vas Interv Radiol JVIR. 2005;16(7):981–90.CrossRefGoogle Scholar
  25. 25.
    Peng ZW, Liang HH, Chen MS, et al. Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. Eur J Surg Oncol. 2008;34(2):166–72.CrossRefGoogle Scholar
  26. 26.
    Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234(3):961–7.CrossRefGoogle Scholar
  27. 27.
    Gandhi S, Iannitti DA, Mayo-Smith WW, Dupuy DE. Technical report: lipiodol-guided computed tomography for radiofrequency ablation of hepatocellular carcinoma. Clin Radiol. 2006;61(10):888–91.CrossRefGoogle Scholar
  28. 28.
    Miyayama S, Yamashiro M, Yoshie Y, et al. Hepatocellular carcinoma in the caudate lobe of the liver: variations of its feeding branches on arteriography. Jpn J Radiol. 2010;28(8):555–62.CrossRefGoogle Scholar
  29. 29.
    Peng ZW, Chen MS. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. Oncology. 2013;84(Suppl 1):40–3.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  • Bo-Ching Lee
    • 1
  • Kao-Lang Liu
    • 1
  • Chih-Horng Wu
    • 1
  • Kai-Wen Huang
    • 2
  • Cheng-Maw Ho
    • 2
  • Rey-Heng Hu
    • 2
  • Ming-Chih Ho
    • 2
  • Yao-Ming Wu
    • 2
  • Po-Huang Lee
    • 2
    • 3
  • Po-Chin Liang
    • 1
  1. 1.Department of Medical ImagingNational Taiwan University HospitalTaipei CityTaiwan
  2. 2.Department of SurgeryNational Taiwan University Hospital and National Taiwan University, College of MedicineTaipei CityTaiwan
  3. 3.Department of SurgeryE-Da HospitalKaohsiungTaiwan

Personalised recommendations